Intravitreal ranibizumab for choroidal neovascularization in a patient with angioid streaks and multiple evanescent white dots

BMC Ophthalmol. 2016 Jul 26:16:122. doi: 10.1186/s12886-016-0307-0.

Abstract

Background: To report a patient with angioid streaks (ASs) and coincident multiple evanescent white dot syndrome (MEWDS) who developed choroidal neovascularization (CNV).

Case presentation: A 20-year-old woman presented with reduced vision (20/100) in her left eye (LE). Based on a complete ophthalmologic examination the patient was diagnosed with ASs and coincident MEWDS. Two weeks later best-corrected visual acuity (BCVA) improved up to 20/25 and the MEWDS findings almost disappeared. Two months later BCVA dropped again (20/100) due to the development of CNV which was treated by a single intravitreal injection of ranibizumab (0.5 mg/0.05 mL). One month after this BCVA improved up to 20/40, and there was regression of the CNV. There was no need for retreatment at the last follow-up visit, 1 year after the ranibizumab injection, when the patient showed further recovery of BCVA up to 20/25.

Conclusions: In this case of ASs, MEWDS completely resolved after 2 weeks, but 2 months later CNV developed. A single intravitreal injection of ranibizumab had a long-lasting effect. Larger series are necessary to clarify the pathogenesis of CNV in such cases and the role of intravitreal ranibizumab.

Keywords: Angioid streaks; Choroidal neovascularization; Multiple evanescent white dots; Ranibizumab.

Publication types

  • Case Reports

MeSH terms

  • Angiogenesis Inhibitors / administration & dosage*
  • Angioid Streaks / complications
  • Choroidal Neovascularization / drug therapy*
  • Female
  • Humans
  • Intravitreal Injections
  • Ranibizumab / administration & dosage*
  • Retinal Diseases / complications*
  • Treatment Outcome
  • Young Adult

Substances

  • Angiogenesis Inhibitors
  • Ranibizumab